Literature DB >> 22829440

A tail with a thorn in it: second-generation antipsychotics hand in hand with statins.

Ronen Durst1, Eran Leitersdorf.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22829440     DOI： 10.1007/s11883-012-0262-z

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  15 in total

1.  AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  J Am Coll Cardiol       Date:  2011-11-03       Impact factor: 24.094

2.  Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect.

Authors:  Jill M Williams; Douglas M Ziedonis; Francisca Abanyie; Marc L Steinberg; Jonathan Foulds; Neal L Benowitz
Journal:  Schizophr Res       Date:  2005-06-14       Impact factor: 4.939

3.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

Review 4.  Antipsychotics in the treatment of schizophrenia: an overview.

Authors:  Rajiv Tandon
Journal:  J Clin Psychiatry       Date:  2011       Impact factor: 4.384

5.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

6.  Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.

Authors:  J Schoemaker; D Naber; P Vrijland; J Panagides; R Emsley
Journal:  Pharmacopsychiatry       Date:  2010-03-04       Impact factor: 5.788

7.  A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.

Authors:  Donald C Goff; Lisa M Sullivan; Joseph P McEvoy; Jonathan M Meyer; Henry A Nasrallah; Gail L Daumit; Steven Lamberti; Ralph B D'Agostino; Thomas S Stroup; Sonia Davis; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2005-09-28       Impact factor: 4.939

8.  Suicide in schizophrenics, manics, depressives, and surgical controls. A comparison with general population suicide mortality.

Authors:  M T Tsuang
Journal:  Arch Gen Psychiatry       Date:  1978-02

9.  Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival.

Authors:  M T Tsuang; R F Woolson; J A Fleming
Journal:  Arch Gen Psychiatry       Date:  1980-09

10.  Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.

Authors:  K P Grootens; N M J van Veelen; J Peuskens; B G C Sabbe; E Thys; J K Buitelaar; R J Verkes; R S Kahn
Journal:  Schizophr Bull       Date:  2009-06-19       Impact factor: 9.306
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.